Olink Holding Ab Publ's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Olink Holding Ab Publ (OLK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Olink Holding Ab Publ vs Its Competitors
- TTM: Trailing 12-month revenue of 169M vs 81,203M combined for tracked competitors (0.2% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+2.6%) for its tracked peer group.
- Growth: Olink Holding Ab Publ generated 21.2% revenue growth year over year in Q4 2023, vs -0.7% for its tracked competitors combined.
- Profitability: Its -18.7% net margin compares with 14.3% for the peer group.
- Peer revenue share: Olink Holding Ab Publ accounted for 0.8% of combined revenue among its tracked peer group, up from 0.7% a year earlier.
- Peer differentiation: Revenue per employee of $0.42M compares with $0.38M for the peer group (1.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OLK Sales vs. its Competitors, Q4 2023
Olink Holding Ab Publ reported revenue growth of 21.18 % year on year in Q4 2023, above its competitors' combined revenue change of -0.72 %.
With a net margin of -18.65 %, Olink Holding Ab Publ reported lower profitability than its competitors (14.28 %).
Olink Holding Ab Publ generated 0.81 % of the combined sales of its peer group, up from 0.66 % a year earlier.
Olink Holding Ab Publ vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Olink Holding Ab Publ reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Olink Holding Ab Publ and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Olink Holding Ab publ | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (2) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Olink Holding Ab Publ's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.2% year over year, combined, vs 21.2% for Olink Holding Ab Publ. Olink Holding Ab Publ's share of combined industry revenue moved from 1.47% to 1.57%, a gain of 0.10 percentage points.
Olink Holding Ab Publ's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Olink Holding Ab publ | No | Yes | Yes | Yes |
| Competitors combined (21) | ||||
| High-Confidence Competitors (4) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 87.50 % (7 of 8) | 75.00 % (6 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OLK Stock Performance relative to its Competitors
OLK Stock Performance relative to High-Confidence Competitors
OLK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | 10x Genomics Inc | 282.9% | Outperformed |
| 2 | Illumina Inc | 282.9% | Outperformed |
| 3 | Nautilus Biotechnology Inc | 282.9% | Outperformed |
| 4 | Harvard Bioscience Inc | 282.9% | Outperformed |
| 5 | Revvity Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Olink Holding Ab Publ's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Olink Holding Ab Publ's Comment on Competition and Industry Peers
Publicly Traded Peers of Olink Holding Ab publ
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Olink Holding Ab publ | 3,233.95 | 169.46 |
| Thermo Fisher Scientific Inc | 249,987.22 | 46,336.00 |
| Agilent Technologies inc | 48,978.81 | 7,372.00 |
| Illumina Inc | 41,221.26 | 4,493.00 |
| Mettler toledo International Inc | 33,683.57 | 4,133.88 |
| Revvity Inc | 17,723.34 | 2,911.81 |
| SUBTOTAL | 447,213.10 | 81,372.02 |
Sign in to see all competitors of Olink Holding Ab publ .
Sources: Olink Holding Ab publ's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Olink Holding Ab publ versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Olink Holding Ab Publ's Competitors Named by the Company
Competitive relationships identified from Olink Holding Ab Publ reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nautilus Biotechnology Inc | Company report | 85% |
| Quanterix Corporation | Company report | 85% |
| Luminex Corporation | Company report | 85% |
| SomaLogic Inc. | Company report | 85% |
| Meso Scale Diagnostics LLC | Company report | 85% |
| Bruker Corporation | Company report | 85% |
| Qiagen N v | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Olink Holding Ab Publ's named competitors require a Commercial License.
Methodology: relationships are extracted from Olink Holding Ab Publ reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Olink Holding Ab Publ's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Agilent Technologies inc | Agilent CrossLab 41.36 % |
| Illumina Inc | Sequencing 90.94 % |
| Mettler toledo International Inc | US Operations 34.31 % |
| Avantor Inc | VWR Distribution & Services 71.73 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Olink Holding Ab publ .
Olink Holding Ab Publ's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Olink Holding Ab publ | 3,234 | 423,653 | -79,000 |
| Thermo Fisher Scientific Inc | 249,987 | 370,688 | 55,912 |
| Agilent Technologies inc | 48,979 | 407,293 | 79,558 |
| Illumina Inc | 41,221 | 3,510,156 | 644,531 |
| Mettler toledo International Inc | 33,684 | 249,029 | 54,555 |
| Revvity Inc | 17,723 | 264,710 | 21,596 |
| PEERS TOTAL | 443,979 | 379,982 | 47,097 |
Sign in to see all peers for Olink Holding Ab publ .
Olink Holding Ab Publ's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Agilent Technologies inc | Americas 41.63 % |
| Illumina Inc | United States and Canada 56.34 % |
| Mettler toledo International Inc | Us Operations segment 34.31 % |
| Qiagen N v | United States 49.08 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Olink Holding Ab publ .
Olink Holding Ab Publ's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Laboratory Analytical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (49 companies). See the full Laboratory Analytical Instruments industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 67.54 % | 37.80 % (avg) | +29.7 pp |
| Operating Margin | -29.67 % | industry median | +4.0 pp |
| EBITDA Margin | -23.04 % | -17.84 % (avg) | -5.2 pp |
| Capital Intensity (Capex / Revenue) | 11.21 % | 8.07 % (avg) | +3.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Olink Holding Ab Publ's Valuation vs Competitive Position
Valuation multiples vs the Laboratory Analytical Instruments industry average (49 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Laboratory Analytical Instruments industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 31.4x | - |
| EV / EBITDA | - | 21.4x | - |
| P/B | 5.9x | 2.9x | +3.0x |
| Return on Equity | -6.29 % | industry aggregate | -6.43 % |
| Return on Invested Capital | -4.55 % | -10.41 % (avg) | 5.86 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Olink Holding Ab Publ's Strategic Group Map
Every company in Olink Holding Ab Publ's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Olink Holding Ab Publ is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Olink Holding Ab Publ's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 11.21 % vs industry average 8.07 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Olink Holding Ab Publ's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Olink Holding Ab Publ's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Olink Holding Ab Publ's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Olink Holding Ab Publ falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Olink Holding Ab Publ's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Return on equity 6.4 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (38.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Olink Holding Ab Publ's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Olink Holding Ab publ | 2.18 | 4.75 | - |
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Agilent Technologies inc | 0.77 | 2.02 | 1.02 |
| Illumina Inc | - | 1.74 | 0.75 |
| Mettler toledo International Inc | 0.04 | 1.13 | - |
| Revvity Inc | 0.74 | 1.74 | 0.45 |
Sign in to see all peers for Olink Holding Ab publ .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Olink Holding Ab Publ's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Olink Holding Ab publ | Q4 2023 | +21.2 % | - |
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Agilent Technologies inc | Q2 2026 | +8.1 % | +7.7 % |
| Illumina Inc | Q2 2026 | +9.4 % | -11.9 % |
| Mettler toledo International Inc | Q2 2026 | +4.5 % | +15.1 % |
| Revvity Inc | Q2 2026 | +1.3 % | -3.9 % |
| PEERS TOTAL | +7.7 % | +14.4 % |
Sign in to see all peers for Olink Holding Ab publ .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Olink Holding Ab Publ's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Olink Holding Ab publ | Q4 2023 | +21.6 % | +164.8 % |
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Agilent Technologies inc | Q2 2026 | -1.6 % | -22.3 % |
| Illumina Inc | Q2 2026 | +6.9 % | +33.3 % |
| Mettler toledo International Inc | Q2 2026 | +30.3 % | +16.4 % |
| Revvity Inc | Q2 2026 | -4.5 % | -41.3 % |
Sign in to see all peers for Olink Holding Ab publ .
Olink Holding Ab Publ's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Olink Holding Ab publ | - | - | - |
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Agilent Technologies inc | 10.97% | 19.84% | 41.99% |
| Illumina Inc | 12.68% | 19.61% | 31.08% |
| Mettler toledo International Inc | 24.86% | 34.41% | - |
| Revvity Inc | 1.97% | 2.18% | 3.27% |
Sign in to see all peers for Olink Holding Ab publ .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Olink Holding Ab Publ's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Olink Holding Ab publ | - | 19.08 |
| Thermo Fisher Scientific Inc | 36.27 | 5.40 |
| Agilent Technologies inc | 34.14 | 6.64 |
| Illumina Inc | 50.45 | 9.17 |
| Mettler toledo International Inc | 37.73 | 8.15 |
| Revvity Inc | 76.70 | 6.09 |
| PEERS AVERAGE | 44.57 | 5.50 |
Sign in to see all peers for Olink Holding Ab publ .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.